 |
|
|
| |
48 Week Bone Marker Changes in Dolutegravir (DTG; GSK1349572) Plus Abacavir/Lamivudine (ABC/3TC) vs Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial
|
| |
| |
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September
10-13, 2013; Denver, CO
P Tebas,1P Kumar,2C Hicks,3C Granier,4B Wynne,5K Pappa,6S Min61University of Pennsylvania, Philadelphia, PA, USA; 2Georgetown University School of Medicine, Washington, DC, USA; 3Duke University Medical Center, Durham, NC, USA; 4-6GlaxoSmithKline, 4London, UK; 5Philadelphia, PA, USA; 6Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
